Cost-effectiveness of clopidogrel

PharmacoEconomics

Volumn 22, Issue SUPPL. 4, 2004, Pages 1-3

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL;

ANGIOPLASTY; ARTERY DISEASE; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HIGH RISK POPULATION; INCIDENCE; LIFE EXPECTANCY; LONG TERM CARE; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SHORT COURSE THERAPY; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; STENT; SURVIVAL; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

EID: 11244255230     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422004-00002     Document Type: Conference Paper

References (15)

1. World Health Organization. The world health report 2004 - changing history. Geneva: World Health Organization; 2004.
2. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163: 884-92
3. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143: 961-5
4. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458-66
5. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
6. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33
7. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20
8. Braunwald E, Antman E, Beasley J, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106: 1893-900
9. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40
10. Weintraub W, Mahoney EM, Lamy A, et al. Long-term cost effectiveness of platelet inhibition with clopidogrel in patients presenting with acute coronary syndromes: results from the CURE trial [Abstract]. Circulation 2003; 108: 1925
11. Mahoney EM, Mehta S, Lamy A, et al. Long-term cost effectiveness of platelet inhibition with clopidogrel in patients undergoing PCI after presenting with an acute coronary syndrome: results from PCI-CURE [Abstract]. Circulation 2003; 108: 2625
12. Beinart S, Kolm P, Veledar E, et al. Short and long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel following percutaneous coronary intervention: results from CREDO [Abstract]. Circulation 2003; 108: 3495
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
14. Annemans L, Lamotte M, Levy E, Lenne X. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Med Econ 2003; 6: 55-68
15. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 2000; 284: 2748-54